Guo Erna, Wei Haotang, Liao Xiwen, Xu Yang, Li Shu, Zeng Xiaoyun
School of Public Health, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
School of International Education, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Oncol Lett. 2018 Apr;15(4):5505-5516. doi: 10.3892/ol.2018.8007. Epub 2018 Feb 9.
Previous studies have reported that alcohol dehydrogenase (ADH) isoenzymes possess diagnostic value in gastric cancer (GC). However, the prognostic value of ADH isoenzymes in GC remains unclear. The aim of the present study was to identify the prognostic value of ADH genes in patients with GC. The prognostic value of ADH genes was investigated in patients with GC using the Kaplan-Meier plotter tool. Kaplan-Meier plots were used to assess the difference between groups of patients with GC with different prognoses. Hazard ratios (HR) and 95% confidence intervals (CI) were used to assess the relative risk of GC survival. Overall, 593 patients with GC and 7 ADH genes were included in the survival analysis. High expression of ADH 1A (class 1), α polypeptide ( log-rank P=0.043; HR=0.79; 95% CI: 0.64-0.99), ADH 1B (class 1), β polypeptide (; log-rank P=1.9×10; HR=0.65; 95% CI: 0.53-0.79) and ADH 5 (class III), χ polypeptide (; log-rank P=0.0011; HR=0.73; 95% CI: 0.6-0.88) resulted in a significantly decreased risk of mortality in all patients with GC compared with patients with low expression of those genes. Furthermore, protective effects may additionally be observed in patients with intestinal-type GC with high expression of (log-rank P=0.031; HR=0.64; 95% CI: 0.43-0.96) and patients with diffuse-type GC with high expression of (log-rank P=0.014; HR=0.51; 95% CI: 0.3-0.88), (log-rank P=0.04; HR=0.53; 95% CI: 0.29-0.98), ADH 4 (class II), π polypeptide (log-rank P=0.033; HR=0.58; 95% CI: 0.35-0.96) and ADH 6 (class V) (log-rank P=0.037; HR=0.59; 95% CI: 0.35-0.97) resulting in a significantly decreased risk of mortality compared with patients with low expression of those genes. In contrast, patients with diffuse-type GC with high expression of (log-rank P=0.044; HR=1.66; 95% CI: 1.01-2.74) were significantly correlated with a poor prognosis. The results of the present study suggest that and may be potential prognostic biomarkers of GC, whereas the prognostic value of other ADH genes requires further investigation.
既往研究报道，酒精脱氢酶（ADH）同工酶在胃癌（GC）中具有诊断价值。然而，ADH同工酶在GC中的预后价值仍不清楚。本研究的目的是确定ADH基因在GC患者中的预后价值。使用Kaplan-Meier绘图工具研究了GC患者中ADH基因的预后价值。Kaplan-Meier图用于评估不同预后的GC患者组之间的差异。风险比（HR）和95%置信区间（CI）用于评估GC生存的相对风险。总体而言，593例GC患者和7个ADH基因纳入了生存分析。ADH 1A（1类）α多肽高表达（对数秩检验P=0.043；HR=0.79；95%CI：0.64-0.99）、ADH 1B（1类）β多肽（；对数秩检验P=1.9×10；HR=0.65；95%CI：0.53-0.79）和ADH 5（Ⅲ类）χ多肽（；对数秩检验P=0.0011；HR=0.73；95%CI：0.6-0.88）与那些基因低表达的患者相比，所有GC患者的死亡风险显著降低。此外，在肠型GC高表达（对数秩检验P=0.031；HR=0.64；95%CI：0.43-0.96）的患者以及弥漫型GC高表达（对数秩检验P=0.014；HR=0.51；95%CI：0.3-0.88）、（对数秩检验P=0.04；HR=0.53；95%CI：0.29-0.98）、ADH 4（Ⅱ类）π多肽（对数秩检验P=0.033；HR=0.58；95%CI：0.35-0.96）和ADH 6（Ⅴ类）（对数秩检验P=0.037；HR=0.59；95%CI：0.35-0.97）的患者中可能观察到额外的保护作用，与那些基因低表达的患者相比，死亡风险显著降低。相反，弥漫型GC高表达（对数秩检验P=0.044；HR=1.66；95%CI：1.01-2.74）的患者与预后不良显著相关。本研究结果表明，和可能是GC潜在的预后生物标志物，而其他ADH基因的预后价值需要进一步研究。
